Karine Khatchadourian1, Shazhan Amed2, Daniel L Metzger2. 1. Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: kkhatchadourian@cw.bc.ca. 2. Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVE: To describe patient characteristics at presentation, treatment, and response to treatment in youth with gender dysphoria. STUDY DESIGN: A retrospective chart review of 84 youth with a diagnosis of gender dysphoria seen at BC Children's Hospital from 1998-2011. RESULTS: Of the 84 patients, 45 (54%) identified as female-to-male (FtM), 37 (44%) as male-to-female (MtF), and 2 (2%) as natal males who were undecided. Median age of presentation was 16.9 years (range 11.4-19.8 years) and 16.6 years (range 12.3-22.5 years) for FtM and MtF youth, respectively. Gonadotropin-releasing hormone analog treatment was prescribed in 27 (32%) patients. One FtM patient developed sterile abscesses with leuprolide acetate; he was switched to triptorelin and tolerated this well. Cross-sex hormones were prescribed in 63 of 84 patients (39 FtM vs 24 MtF, P < .02). Median age at initiation of testosterone injections in FtM patients was 17.3 years (range 13.7-19.8 years); median age at initiation of estrogen therapy in MtF patients was 17.9 years (range 13.3-22.3 years). Three patients stopped cross-sex hormones temporarily due to psychiatric comorbidities (2 FtM) and distress over androgenic alopecia (1 FtM). No severe complications were noted in patients treated with testosterone or estrogen. CONCLUSION: Treatment with gonadotropin-releasing hormone analog and/or cross-sex hormones, in collaboration with transgender-competent mental health professionals, is an intervention that appears to be appropriate in carefully selected youth with gender dysphoria. Long-term follow-up studies are needed to determine the safety of these treatments in this age group.
OBJECTIVE: To describe patient characteristics at presentation, treatment, and response to treatment in youth with gender dysphoria. STUDY DESIGN: A retrospective chart review of 84 youth with a diagnosis of gender dysphoria seen at BC Children's Hospital from 1998-2011. RESULTS: Of the 84 patients, 45 (54%) identified as female-to-male (FtM), 37 (44%) as male-to-female (MtF), and 2 (2%) as natal males who were undecided. Median age of presentation was 16.9 years (range 11.4-19.8 years) and 16.6 years (range 12.3-22.5 years) for FtM and MtF youth, respectively. Gonadotropin-releasing hormone analog treatment was prescribed in 27 (32%) patients. One FtM patient developed sterile abscesses with leuprolide acetate; he was switched to triptorelin and tolerated this well. Cross-sex hormones were prescribed in 63 of 84 patients (39 FtM vs 24 MtF, P < .02). Median age at initiation of testosterone injections in FtM patients was 17.3 years (range 13.7-19.8 years); median age at initiation of estrogen therapy in MtF patients was 17.9 years (range 13.3-22.3 years). Three patients stopped cross-sex hormones temporarily due to psychiatric comorbidities (2 FtM) and distress over androgenic alopecia (1 FtM). No severe complications were noted in patients treated with testosterone or estrogen. CONCLUSION: Treatment with gonadotropin-releasing hormone analog and/or cross-sex hormones, in collaboration with transgender-competent mental health professionals, is an intervention that appears to be appropriate in carefully selected youth with gender dysphoria. Long-term follow-up studies are needed to determine the safety of these treatments in this age group.
Authors: Johanna Olson-Kennedy; Jonathan Warus; Vivian Okonta; Marvin Belzer; Leslie F Clark Journal: JAMA Pediatr Date: 2018-05-01 Impact factor: 16.193
Authors: A D Fisher; J Ristori; G Castellini; C Sensi; E Cassioli; A Prunas; M Mosconi; R Vitelli; D Dèttore; V Ricca; M Maggi Journal: J Endocrinol Invest Date: 2017-03-29 Impact factor: 4.256
Authors: Johanna Olson; Sheree M Schrager; Marvin Belzer; Lisa K Simons; Leslie F Clark Journal: J Adolesc Health Date: 2015-07-21 Impact factor: 5.012
Authors: Nastasja M de Graaf; Thomas D Steensma; Polly Carmichael; Doug P VanderLaan; Madison Aitken; Peggy T Cohen-Kettenis; Annelou L C de Vries; Baudewijntje P C Kreukels; Lori Wasserman; Hayley Wood; Kenneth J Zucker Journal: Eur Child Adolesc Psychiatry Date: 2020-11-09 Impact factor: 4.785
Authors: Jenifer K McGuire; Dianne Berg; Jory M Catalpa; Quin J Morrow; Jessica N Fish; G Nic Rider; Thomas Steensma; Peggy T Cohen-Kettenis; Katherine Spencer Journal: Int J Transgend Health Date: 2020-04-11
Authors: Johanna Olson-Kennedy; Peggy T Cohen-Kettenis; Baudewijntje P C Kreukels; Heino F L Meyer-Bahlburg; Robert Garofalo; Walter Meyer; Stephen M Rosenthal Journal: Curr Opin Endocrinol Diabetes Obes Date: 2016-04 Impact factor: 3.243